Exelixis, Inc. (EXEL) — ESG & Values Scores

Environment story

Exelixis discloses minimal direct environmental metrics. Scope 1 and Scope 2 emissions are not reported in available filings. No net-zero target year is disclosed. The company acknowledges regulatory compliance with environmental laws but provides no quantified sustainability goals, carbon reduction initiatives, or renewable energy commitments. No major environmental controversies, toxic-waste incidents, or water-use disputes are documented. The company states it does not expect material compliance costs for environmental regulations. Absence of disclosed decarbonization infrastructure, renewable energy adoption, or supply-chain carbon accounting prevents higher scoring.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Environmental Health and Safety Compliance

Company maintains compliance with federal, state, and local environmental laws governing hazardous materials use, storage, and disposal. Lab Safety Committee oversees working conditions and conducts regular safety inspections.

Operational risk mitigation; no quantified emission reductions or decarbonization targets disclosed.

Social story

Exelixis does not disclose CEO-to-median-worker pay ratio, workforce turnover rates, or diversity metrics (gender/race/ethnicity) for workforce or leadership in the 10-K filing reviewed. No documented union-suppression activities, strikes, or labor disputes within the last 24 months are evident. The company emphasizes oncology focus and employee support for lab safety and clinical work, but lacks formal diversity program disclosures, EEO-1 data, or supply-chain human-rights audits. No forced-labor, conflict-minerals, or modern-slavery statements are present. The company operates patient-access programs (EASE) and provides co-pay assistance and reimbursement support, indicating some commitment to healthcare equity. Absence of disclosed diversity targets and pay-equity commitments limits social pillar score.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Exelixis Access Services (EASE)

Comprehensive reimbursement and patient support program providing co-pay assistance to commercially insured patients, free drug to uninsured/underinsured patients meeting financial criteria, prior authorization assistance, benefits investigation, appeals support, treatment coordination, and clinical outreach from oncology nurses.

Enhances patient access and healthcare equity for cancer patients; no quantified participation or cost metrics disclosed.
Employee Lab Safety Training and Oversight

Training on chemical hygiene, personal protective equipment, blood-borne pathogen handling. Lab Safety Committee conducts regular safety inspections. Industrial hygiene monitoring and equipment certification (fume hoods, biosafety cabinets) for hazardous-chemical workers.

Occupational safety risk mitigation; no quantified incident rates or safety metrics disclosed.

Governance story

Board independence percentage is not disclosed in the 10-K. No dual-class share structure is mentioned; single common stock class is implied. Annual lobbying expenditures are not itemized in the filing. No significant active antitrust, consumer-safety, or financial-fraud regulatory proceedings are disclosed. The company faces drug-pricing policy and regulatory reimbursement pressures from the IRA and potential MFN pricing initiatives, but no formal lobbying against environmental or consumer-protection deregulation is documented. Patent litigation with generic manufacturers (Azurity, Biocon, others) is noted but resolved or managed through settlement. The company has a joint steering committee structure with commercial partners (Ipsen, Takeda) and a joint development committee with BMS, indicating collaborative governance. Absence of disclosed board-independence percentage and lobbying spend limits score to mid-range.

Criticisms on file

Generic drug competition and patent litigation: ANDAs submitted by MSN, Teva, Cipla, Biocon, Sun; 505(b)(2) applications by Handa (capsules) and Azurity (tablets). Settlement agreement with Biocon in July 2025. USPTO declined inter partes reviews by Azurity in June and July 2025. Patent expiration risk disclosed as material risk factor.
Source: SEC 10-K Form 000093976726000021, Item 1A Risk Factors; MD&A Section 2025 Business Updates.

Disclosed initiatives

Joint Steering Committee Governance (Ipsen Collaboration)

Collaboration agreement with Ipsen includes joint steering committee and subcommittees to guide and oversee collaboration operation and strategic direction. Exelixis retains final decision-making authority on cabozantinib development. Supply agreement and quality agreement define manufacturing responsibilities.

Structured partner oversight; risk mitigation through shared governance on major cabozantinib franchise decisions.
Joint Development Committee (BMS Collaboration)

Clinical trial collaboration with BMS includes joint development committee governing partnership for evaluation of cabozantinib in combination with nivolumab and ipilimumab. Cost-sharing determined on trial-by-trial basis.

Collaborative development governance; aligned incentives for dual-therapy trial execution.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Exelixis, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Exelixis, Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)